Sung H, Ferlay J, Siegel RL, et al. global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49.

Article  PubMed  Google Scholar 

Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.

Article  CAS  PubMed  Google Scholar 

Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy: 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1389–96.

Article  CAS  PubMed  Google Scholar 

Yoshikawa T, Terashima M, Mizusawa J, et al. Four courses versus eight cofor patients wurses of adjuvant S-1 ith stage II gastric cancer: an open-label, phase 3, non-inferiority, randomised trial. Lancet Gastroenterol Hepatol. 2019;4:208–16.

Article  PubMed  Google Scholar 

National Comprehensive Cancer Network. Gastric Cancer. Version 2019. Accessed December 15, 2020.

Smyth EC, Verheij M, Allum W, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:38–49.

Article  Google Scholar 

Wang FH, Zhang XT, Li YF, et al. The Chinese society of clinical oncology: clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun. 2021;08:41.

Google Scholar 

Yeh CN, Jung SM, Chen TW, et al. Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy. Langenbecks Arch Surg. 2010;395:217–25.

Article  PubMed  Google Scholar 

Baretti M, Le DT. DNA mismatch repair in cancer. Pharmacol Ther. 2018;189:45–62.

Article  CAS  PubMed  Google Scholar 

Zhao F, Yuan X, Ren D, et al. Predicting the efficacy of 5-fluorouracil-based adjuvant chemotherapy in gastric cancer by microsatellite instability: a meta-analysis. J Environ Pathol Toxicol Oncol. 2019;38:21–8.

Article  PubMed  Google Scholar 

Smyth EC, Wotherspoon A, Peckitt C, et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the medical research council adjuvant gastric infusional chemotherapy trial. JAMA Oncol. 2017;3:1197–203.

Article  PubMed  Google Scholar 

An JY, Kim H, Cheong JH, et al. Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection. Int J Cancer. 2012;131:505–11.

Article  CAS  PubMed  Google Scholar 

Oki E, Kakeji Y, Zhao Y, et al. Chemosensitivity and survival in gastric cancer patients with microsatellite instability. Ann Surg Oncol. 2009;16:2510–5.

Article  PubMed  Google Scholar 

Giampieri R, Maccaroni E, Mandolesi A, et al. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy. Gastric Cancer. 2017;20:156–63.

Article  CAS  PubMed  Google Scholar 

Beal EW, Wei L, Ethun CG, et al. Elevated NLR in gallbladder cancer and cholangiocarcinoma-making bad cancers even worse: results from the US Extrahepatic Biliary Malignancy Consortium. HPB (Oxford). 2016;18(11):950–7.

Article  PubMed  Google Scholar 

Spolverato G, Maqsood H, Kim Y, et al. Neutrophil-lymphocyte and platelet-lymphocyte ratio in patients after resection for hepato-pancreatico-biliary malignancies. J Surg Oncol. 2015;111:868–74.

Article  CAS  PubMed  Google Scholar 

Guo Y-H, Sun H-F, Zhang Y-B, et al. The clinical use of the platelet/lymphocyte ratio and lymphocyte/monocyte ratio as prognostic predictors in colorectal cancer: a meta-analysis. Oncotarget. 2017;8:20011–24.

Article  PubMed  PubMed Central  Google Scholar 

Namikawa T, Maeda M, Yokota K, et al. Assessment of systemic inflammatory response and nutritional markers in patients with trastuzumab-treated unresectable advanced gastric cancer. In Vivo. 2020;34:2851–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nie RC, Chen GM, Yuan SQ, et al. Adjuvant chemotherapy for gastric cancer patients with mismatch repair deficiency or microsatellite instability: systematic review and meta-analysis. Ann Surg Oncol. 2022;29:3193–3193.

Article  PubMed  Google Scholar 

Laiho P, Launonen V, Lahermo P, et al. Low-level microsatellite instability in most colorectal carcinomas. Cancer Res. 2002;62:1166–70.

CAS  PubMed  Google Scholar 

Choi YH, Lee JW, Lee SH, et al. A high monocyte-to-lymphocyte ratio predicts poor prognosis in patients with advanced gallbladder cancer receiving chemotherapy. Cancer Epidemiol Biomarkers Prev. 2019;28:1045–51.

Article  CAS  PubMed  Google Scholar 

Chen L, Yan Y, Zhu L, et al. Systemic immune-inflammation index as a useful prognostic indicator predicts survival in patients with advanced gastric cancer treated with neoadjuvant chemotherapy. Cancer Manag Res. 2017;9:849–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li J, Zhang Y, Xu Q, et al. Systemic inflammatory markers of resectable colorectal cancer patients with different mismatch repair gene status. Cancer Manag Res. 2021;13:2925–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Choi YY, Kim H, Shin SJ, et al. Microsatellite instability and programmed cell death-ligand 1 expression in stage II/III gastric cancer: post hoc analysis of the CLASSIC randomized controlled study. Ann Surg. 2019;08:270.

Google Scholar 

Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247–57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Polom K, Marano L, Marrelli D, et al. Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer. Br J Surg. 2018;02:105.

Google Scholar 

Kim SY, Choi YY, An JY, et al. The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: results from a large cohort with subgroup analyses. Int J Cancer. 2015;137:819–25.

Article  CAS  PubMed  Google Scholar 

Shen H, Zhong M, Wang W, et al. EBV infection and MMR status significantly influence the clinical outcomes of gastric cancer patients. Clin Chim Acta. 2017;471:216–21.

Article  CAS  PubMed  Google Scholar 

Pietrantonio F, Miceli R, Raimondi A, et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol. 2019;12(10):37.

Google Scholar 

Tsai CY, Lin TA, Huang SC, et al. Is adjuvant chemotherapy necessary for patients with deficient mismatch repair gastric cancer?-Autophagy inhibition matches the mismatched. Oncologist. 2020;25:e1021–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Diakos CI, Charles KA, McMillan DC, et al. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15:e493-503.

Article  PubMed  Google Scholar 

Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krenn-Pilko S, Langsenlehner U, Thurner EM, et al. The elevated preoperative platelet-to-lymphocyte ratio predicts poor survival in breast cancer patients. Br J Cancer. 2014;110:2524–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee JH, Kang BH, Song C, et al. Microsatellite instability correlated inflammatory markers and their prognostic value in the rectal cancer following neoadjuvant chemoradiotherapy: a hypothesis-generating study. In Vivo. 2020;34:2119–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marín Hernández C, Piñero Madrona A, Gil Vázquez PJ, et al. Usefulness of lymphocyte-to-monocyte, neutrophil-to-monocyte and neutrophil-to-lymphocyte ratios as prognostic markers in breast cancer patients treated with neoadjuvant chemotherapy. Clin Transl Oncol. 2018;20:476–83.

Article  PubMed  Google Scholar